Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoid Pulse Therapy in Severe Cerebral Venous Thrombosis (Proteomics-integrated RCT)
ChiCTR2600124390Phase 3Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylprednisolone in cerebral sinovenous thrombosis (CSVT) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Proportion of good functional outcome at 90 days (mRS 0–2). Planned start May 2026; status: not yet recruiting.
02
Drugs
methylprednisolone
03
Conditions
cerebral sinovenous thrombosis (CSVT)
Beyond the preview
Go deeper on ChiCTR2600124390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124390.